Acquired factor XII deficiency in a woman with recurrent pregnancy loss: working on a differential diagnosis in a single case by D'Uva, Maristella et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Methodology
Acquired factor XII deficiency in a woman with recurrent 
pregnancy loss: working on a differential diagnosis in a single case
Maristella D'Uva, Ida Strina, Antonio Mollo, Antonio Ranieri, Giuseppe De 
Placido and Pierpaolo Di Micco*
Address: Dipartimento Universitario di Scienze Ostetriche Ginecologiche e Medicina della Riproduzione, Area Funzionale di Medicina della 
Riproduzione ed Endoscopia Ginecologica, Università degli Studi di Napoli Federico II, via Pansini 5 Building 9, 80131, Naples, Italy; 
*Thrombosis Center, Istituto Clinico Humanitas "IRCCS", via Manzoni 56, 20089, Rozzano – Milano – Italy
Email: Maristella D'Uva - maryduva@yahoo.it; Ida Strina - maryduva@yahoo.it; Antonio Mollo - antmollo@unina.it; 
Antonio Ranieri - dott_pie@libero.it; Giuseppe De Placido - antmollo@unina.it; Pierpaolo Di Micco* - pdimicco@libero.it
* Corresponding author    
Abstract
Background: Antiphospholipid syndrome (APS) has been often associated to RPL since 1980 and
some reports in the Literature rarely described antibodies to factor XII in patients with APS.
Case history: We report the case history of 34-year-old caucasian women with recurrent fetal
loss and persistent prolonged activated partial thromboplastin time. Haemostatic tests revealed
persistent light decrease of clotting factor XII with normal values of IgG and IgM anticardiolipin
antibodies and transient positivity for lupus anticoagulant (LA). Few reports in the Literature
described antibodies to factor XII in patient with antiphospholipid syndrome (APS) and transient
LA. So, once other causes of RPL were excluded, the patient was diagnosed an unusual form of APS
associated to antibodies to factor XII, reduced factor XII plasma levels, transient LA and prolonged
activated partial thromboplastin time.
Discussion: We suggest to consider also antibodies directed to clotting factors (e.g. factor XII in
our case) as second step of thrombophilia screening in RPL, in particular if a persistent prolonged
aPTT is present without an apparent cause.
Background
Recurrent pregnancy loss (RPL) is one of the most com-
mon cause of sterility. An our recent study underlined the
relevant role of d-dimer, as marker of hypercoagulable
state, to identify thrombophilia in women affected by pri-
mary or secondary sterility [1]
In 1999 a study written by Brenner et al. identified throm-
bophilia as principal cause of more than 40% of women
affected by RPL [2]. Further studies underlined a pathoge-
netic role of inherited thrombophilia in women affected
by RPL. Sanson et al., in fact, reported an increased fre-
quency of antithrombin III, protein C and protein S defi-
ciency in women with RPL [3], while Grandone et al.
found an increased incidence of factor V Leiden in women
with unexplained RPL [4]. Also prothrombin A20210G
gene polymorphism has been reported as possible cause
of RPL in several studies [2,5,6].
Yet, also acquired thrombophilia has been associated to
RPL. A study by Dossenbach et al., in fact, revealed that
elevated maternal plasma levels of clotting factor VIII tend
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to be associated to an increased risk of RPL [7]. Moreover,
several studies in the Literature are available for the asso-
ciation of RPL and primary or secondary antiphospholi-
pid syndrome [8,9]. On this topic also a rare condition as
acquired deficiency of clotting factor XII has been
described. Braulke et al. identified for the first time a fac-
tor XII deficiency in RPL [10], but subsequently Jones et
al. reported acquired factor XII deficiency in a subpopula-
tion of women with antiphospholipid antibodies and RPL
[11-13]. We here report a really interesting case report of
woman affected by unexplained RPL, prolonged activated
partial thrombplastin time and mild/moderate reduction
of clotting factor XII.
Case presentation
A 34-year-old Caucasian non smoking woman was
referred to our Sterility Center. Her personal anamnesis
revealed three early pregnancy loss within 8 and 12 week
of gestation and one extrauterine pregnancy. The patient
did not revealed previous thromboembolic disease (arte-
rial or venous) nor haemorragic disorders; moreover
patient was not ongoing any type of pharmacological
treatment. A thorough familial anamnesis did not show a
trend toward thromboembolic and/or haemorragic dis-
ease.
To understand pathophysiology of her RPL the patient
performed several laboratory and instrumental tests.
A normal ovarian function and ovulation were detected
by normal values of Follicle-stimulating Hormone,
Luteinising Hormone, oestradiol and progesterone and by
ovarian ultrasound scan (data not shown). Uterine and
salpinxes malformation was excluded by hysterosalp-
ingography and hysteroscopy (data not shown). Endo-
crinological diseases such as diabetes and dysthyroidism
were evaluated and excluded by normal values of glycae-
mia, thriiodothyronine (i.e. FT3), thyroxine (i.e. FT4) and
Thyroid-stimulating Hormone (data not shown). Inflam-
matory chronic diseases were excluded by normal values
of erythro-sedimentation rate and acute phase C reactive
protein and immunopathological chronic disease, such as
erytematosus systemic lupus, by normal level of antinu-
clear antibodies (ANA), anitmithocondrial antibodies
(AMA) and smooth muscle antibodies (SMA) too (data
not shown); moreover patient did not suffer of chronic
joint paint or fever or other related symptoms.
Yet, routine haemostatic tests showed normal value of
prothrombin time, measured as International Normalised
Ratio (PT INR, 1.15) and a prolonged activated thrombo-
plastin time, measured as ratio (aPTT, 1.45) (table 1). To
confirm this laboratory alteration, after 15 days a second
step of haemostatic parameters were tested and confirmed
normal value of PT INR and prolonged aPTT (1.46, table
1 and 2), associated to normal levels of anticardiolipin
antibodies (tested by an ELISA method; IgM 1.7 U/MPL
Table 1: Screening for disorder of haemostasis in the patient with RPL.
Parameters (unit of measurement) Results Normal range
Prothrombin time (INR) 1.15 0.8–1.2
Activated partial thromboplastin time (ratio) 1.45 0.8–1.2
Fibrinogen (mg/dL) 275 220–420
Protein C (%) 93 60–125
Protein S (%) 92 60–125
Antithrombin III (%) 104 80–120
Anticardiolipin Ab IgM (U/GPL) 1.7 < 2.0
Anticardiolipin Ab IgG (U/MPL) 3.9 < 7.0
β-2-GP I Ab Absent Absent
Lupus anticoagulant Absent Absent
Factor XII (%) 65 80–120
Factor XI (%) 113 80–120
Factor X (%) 112 80–120
Factor IX (%) 99 80–120
Factor VIII (%) 88 65–155
Factor V (%) 110 80–120
MTHFRC677T gene polymorphism Wild type Wild type
PTHRA20210 gene polymorphism Wild Type Wild type
FVL gene polymorphism Wild Type Wild type
INR: international normalised ratio
MTHFRC677T: methylene-tetra-hydrp-folate reductase C677T gene polymorphism
PTHRA20210G: prothrombin A20210G gene polymorphism
FVL: factor V Leiden gene polymorphism
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and IgG 3.9 U/GPL) (table 1 and 2), fibrinogen and clot-
ting factors V, VIII, IX, X, XI (table1), while a reduced plas-
matic level of clotting factor XII was detected (65%, table
1 and 2). So, we tested for aPTT and factor XII first degree
relatives (i.e. one sister and parents) but did not find alter-
ations (data not shown). Yet, lupus anticoagulant and
antibodies to β-2-glycoprotein I were absent (table 1 and
2). Furthermore, because RPL was associated to reduced
clotting inhibitors also protein C, protein S and anti-
thrombin III were analysed and resulted in normal range
(table 1) such as inherited thrombophilia associated to
Factor V Leiden and prothrombin A20210G gene poly-
morphisms (table 1). Moreover, to confirm factor XII defi-
ciency, after one month the patient was evaluated again
and results showed again prolonged aPTT (1.48), reduced
factor XII (55%). So, we tested aPTT adding to the plasma
patient's a normal plasma sample with a ratio of plasma
patient's to pool plasma 1/1 v/v; results revealed a partial
correction of aPTT (1.30) suggesting a possible presence
of an acquired clotting inhibitor and/or antiphospholipid
antibodies. A new evaluation of common antiphospholi-
pid antibodies began with normal levels of anticardioli-
pin antibodies (tested again with an ELISA method; IgM
1.5 and IgG 3.8) and absence of antibodies to β-2-Glyco-
protein I, but a positivity for lupus anticoagulant was
detected (table 2). Lupus anticoagulant was assayed
according to recommendations of the International Soci-
ety of Thrombosis and Haemostasis. Furthermore, at this
time we tested again ANA that resulted again negative.
Finally, because a transient positivity of lupus anticoagu-
lant has been associated with factor XII deficiency in
patients with antiphospholipid syndrome in rare cases
[14,15], after one month the patient was evaluated one
more time and in this time also antibodies to clotting fac-
tor XII were evaluated by an ELISA method. Results
showed prolonged aPTT (1.44), reduced factor XII plasma
levels (43%), normal range of anticardiolipin antibodies
(IgM and IgG), absence of antibodies to β-2-Glycoprotein
I, negativity for lupus anticoagulant, while antibodies to
factor XII have been detected (table 2). So, according to
our data and data available in the Literature the patient
was diagnosed an unusual form of primary antiphosphol-
ipid syndrome and an antithrombotic treatment was sug-
gested.
Discussion
Inherited factor XII deficiency seems to be not associated
to bleeding tendency if referred to major surgery [16].
However, some individual with reduction of factor XII
seems to have a trend toward thrombosis [16], but patho-
physiological mechanisms underlying should be better
understood. Therefore, deficiency of clotting factor XII has
been reported as also thrombotic risk factor and Halb-
mayer et al. suggested to consider factor XII deficiency in
patients with recurrent thromboembolism [17]. One of
the possible mechanisms could be associated to the pres-
ence of acquired clotting inhibitors eventually associated
to the presence of an antiphospholipid syndrome [18].
Acquired clotting inhibitors, in fact, have been identified
in several disease and frequently are associated to a
thrombophilic trend [19].
Furthermore, from a clinical point of view, alteration of
haemostasis with a trend toward thrombophilia has been
frequently associated to RPL [2,8]. According to a multi-
variate analysis on the etiology of thrombophilia by
Yamada et al., clotting factor XII deficiency has been
found in 4.2% of women affected by RPL [20]. Another
interesting study by Iinuma et al. underlined clotting fac-
tor XII activity and not its 46C/T gene polymorphism as
cause of RPL in a selected population [21]. However, fac-
tor XII deficiency may be due to inherited deficiency or
acquired deficiency during an acquired disease such as
antiphospholipid syndrome. In this last condition, in fact,
we may find an acquired factor XII deficiency because the
presence of antibodies to factor XII; moreover antibodies
to factor XII may be present during antiphospholipid syn-
drome alone or together to lupus anticoagulant [11]: anti-
bodies to factor XII have been described, in fact, also in
patients with antiphospholipid syndrome and transient
Table 2: Monitor of the alteration of haemostasis in the patient with RPL.
Parameters (Unit of measurement) First screening Second screening Third screening Fourth screening Normal value
aPTT (ratio) 1.45 1.36 1.28 1.44 0.8–1.2
Factor XII (%) 65 50 55 43 80–120
Anticardiolipin Ab IgM (U/MPL) 1.7 1.3 1.5 1.5 < 2.0
Anticardiolipin Ab IgG (U/GPL) 3.9 5.4 3.8 2.5 < 7.0
β-2-GP I Ab Absent Absent Absent Absent Absent
Lupus anticoagulant Absent Absent Present Absent Absent
Anti-factor XII Ab Not tested Not tested Not tested Present Absent
Antinuclear antibodies (ANA) Absent Not tested Not tested Absent Not tested
aPTT: activated partial thromboplastin time
ab: antibodies
β-2-GP I Ab: Antibodies to β-2-glycoprotein IJournal of Translational Medicine 2005, 3:43 http://www.translational-medicine.com/content/3/1/43
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lupus anticoagulant [14,15]. Moreover, Jones et al.
described that antibodies to factor XII can be present in
women with RPL and antiphospholipid syndrome more
than anticardiolipin antibodies and antibodies to β-2-
glycoprotein I [11]. So, according to these data, antibodies
to factor XII may be implicated in the pathophysiology of
the hypercoagulable state in women with antiphospholi-
pid syndrome showing RPL and their incidence in this
clinical setting could be underestimated according to the
data available from the Literature [18]. This hypothesis is
really intriguing also in the case we described.
The reported patient affected by RPL, in fact, did not show
an apparent cause of RPL other than reduction of clotting
factor XII. Also laboratory tests, concerning throm-
bophilia, did not show common alteration of haemosta-
sis associated to RPL such as factor V Leiden gene
polymorphism or reduction of clotting inhibitors (i.e.
protein C, protein S, antithrombin III). Yet, the clinical
presentation and the presence of persistent prolonged
aPTT suggested periodical tests concerning possible clot-
ting factors deficiency and/or the presence of antiphos-
pholipid syndrome. Results of this screening confirmed us
the partial and acquired factor XII deficiency, due to the
presence of antibodies to factor XII, in presence of tran-
sient lupus anticoagulant.
So, in conclusion we suggest to search in such cases also
antibodies directed to clotting factors (e.g. factor XII in
our case) as second step of thrombophilia screening in
RPL, in particular if a persistent prolonged aPTT is present
(figure 1) without an apparent cause.
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